28 September 2023
28 September 2023
Ionis is entitled to receive an upfront payment of $60m from Roche.
Tetra obtained orphan drug designation from the FDA for zatolmilast as an investigational treatment in 2018.
The latest development is based on findings from the Phase III VISIBLE 1 clinical trial.
Apart from the workforce cuts, the company is also considering asset divestment and mergers as part of a strategic review.
The partnership will help advance preclinical concept in the cardiometabolic disorder space from four academic institutions.
The popular acne treatment will soon be available in 15 EU countries in addition to UK and South Africa.
The funding was part of an oversubscribed Series C financing round, which will be used to advance its lead pulmonary fibrosis therapies into Phase II trials.
The introduction of generic pirfenidone will give more patients access to medication that could improve the quality of life of patients living with idiopathic pulmonary fibrosis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.
